tiprankstipranks
Advertisement
Advertisement
Jason Gerberry Maintains Hold on LENZ Therapeutics as Weak VIZZ Launch Spurs Major Sales Forecast Cuts
PremiumRatingsJason Gerberry Maintains Hold on LENZ Therapeutics as Weak VIZZ Launch Spurs Major Sales Forecast Cuts
23d ago
Analyst Maintains Buy on LENZ as VIZZ Adoption, Prescriber Engagement and Patient Refill Trends Support Long-Term Commercial Franchise Growth
Premium
Ratings
Analyst Maintains Buy on LENZ as VIZZ Adoption, Prescriber Engagement and Patient Refill Trends Support Long-Term Commercial Franchise Growth
24d ago
Analyst Maintains Buy on LENZ, Cuts VIZZ Price Target to $10 While Highlighting Strong Patient Persistence and Long-Term Upside
Premium
Ratings
Analyst Maintains Buy on LENZ, Cuts VIZZ Price Target to $10 While Highlighting Strong Patient Persistence and Long-Term Upside
24d ago
LENZ Therapeutics Shareholders Back Board and Auditor Slate
PremiumCompany AnnouncementsLENZ Therapeutics Shareholders Back Board and Auditor Slate
3M ago
Lenz announces Everest Medicines acquired rights to develop VIZZ in China
Premium
The Fly
Lenz announces Everest Medicines acquired rights to develop VIZZ in China
3M ago
Lenz Therapeutics price target lowered to $20 from $26 at Citi
Premium
The Fly
Lenz Therapeutics price target lowered to $20 from $26 at Citi
4M ago
Analyst Reiterates Buy on LENZ Amid Strong Early Commercial Execution and Durable Demand Signals
PremiumRatingsAnalyst Reiterates Buy on LENZ Amid Strong Early Commercial Execution and Durable Demand Signals
4M ago
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
Premium
The Fly
Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright
4M ago
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Premium
The Fly
Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100